The therapeutic potential of targeting SOX2-driven CSC supports the clinical use of iadademstat as a novel anti-SOX2 epigenetic breast cancer therapy, particularly in endocrine therapy-resistant luminal-B cases -which are known employ SOX2 to increase the proportion of CSC-like cells, rendering them insensitive to tamoxifen [34]- and in HER2-positive disease –in which SOX2 overexpression correlates with poor differentiation [67] and HER2-targeted therapies such as trastuzumab fail to eliminate SOX2-overexpressing CSC [68]. Here, ERBB2 is linked to breast cancer.